DVL2 and hepatocellular carcinoma: Similarly, in hepatocellular carcinoma (HCC), toosendanin (TSN), a novel agonist of WWOX, dose-dependently increases WWOX mRNA and protein expression and enhances its interaction with STAT3 and Dvl2, thereby inhibiting both the JAK2/STAT3 and Wnt/β-catenin signaling pathways [34].